FINWIRES · TerminalLIVE
FINWIRES

ASX:OIL

4 stories mentioning ASX:OILUpdated just now

Every FINWIRES story that references ASX:OIL, newest first.

Asia

Optiscan Imaging Says 84 Cases Imaged in Study Using Digital Pathology Imaging Device

Optiscan Imaging (ASX:OIL) said 84 cases were imaged in its digital pathology study with Australian Clinical Labs (ASX:ACL), using its InForm digital pathology imaging device, according to a Thursday Australian bourse filing.The device is providing real-time, slide-free cellular imaging at the point of contact. The cases imaged to date span a broad range of human tissue samples across multiple organs and systems as well as pathologies.

ASX:ACLASX:OIL
Asia

Optiscan Imaging Begins Head, Neck Cancer Imaging Study in US

Optiscan Imaging (ASX:OIL) began a new US-based head and neck cancer imaging study on 35-patients to assess the performance of Optiscan's InVue and InForm imaging platforms in head and neck tumor resections, according to a Tuesday Australian bourse filing.The InVue platform will be used during head and neck tumor resections to capture real-time, in vivo microscopic images within the surgical cavity following tumor removal. Following excision, tissue specimens will be analysed ex vivo using the InForm platform.Patient recruitment was initiated at Mayo Clinic in Rochester.

ASX:OIL
Asia

Optiscan Imaging to Commence US Clinical Study for InVue, InForm Devices in Breast Conserving Surgery, Shares Up 7%

Optiscan Imaging (ASX:OIL) is set to start a US clinical study assessing the safety, performance and workflow utility of its InVue precision surgery imaging device and InForm digital pathology imaging device in patients undergoing breast-conserving surgery, according to a Wednesday Australian bourse filing.The company said the study will evaluate InVue for in vivo surgical imaging and InForm for ex vivo digital pathology imaging in 35 US patients, seeking to validate an integrated surgical-pathology workflow for US market entry and broader clinical expansion.The company's shares rose 7% in recent Wednesday trade.

ASX:OIL
Asia

Optiscan Imaging Says Half of Target Patients Imaged in Human Breast Cancer Imaging Study

Optiscan Imaging (ASX:OIL) said 25 of the target 50 patients were imaged in its first in-human breast cancer imaging study at Royal Melbourne Hospital in Victoria, reaching a halfway mark milestone, according to a Thursday Australian bourse filing.The study is assessing surgical margins in breast cancer patients undergoing lumpectomy procedures using the InVue precision surgery imaging device for in vivo imaging and the InForm digital pathology imaging device for ex vivo imaging, per the filing.InVue is used intraoperatively in the resection cavity to generate live in vivo images immediately after tumor removal, while InForm is used to analyze the excised tissue.Clinical readouts of the analyzed cases to date show nine with clear margins, four with narrowly clear margins, and five with involved margins, the company said. There were no reported adverse events related to intravenous sodium fluorescein contrast agent injections.The study was expanded to a second clinical site to accelerate recruitment.

ASX:OIL

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:OIL in your portfolio
WheelAI
WheelAI
Analyze ASX:OIL options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:OIL